In­ovio spin­out plans piv­otal study for can­cer vac­cine as it touts al­ter­na­tive take on PhIb/IIa liv­er can­cer da­ta

In­ovio spin­out Ge­neos Ther­a­peu­tics said Tues­day that it has three new par­tial re­spons­es and one case of sta­ble dis­ease from a mid-stage liv­er can­cer tri­al test­ing its per­son­al­ized can­cer vac­cine can­di­date in com­bi­na­tion with Mer­ck’s Keytru­da. How­ev­er, the biotech is claim­ing these re­spons­es as “com­plete mol­e­c­u­lar re­spons­es.”

Ge­neos re­port­ed the four “com­plete mol­e­c­u­lar re­spons­es” Tues­day morn­ing, tout­ing an analy­sis of the pa­tient’s cir­cu­lat­ing tu­mor DNA, or ctD­NA. That met­ric of­fers a dif­fer­ent pic­ture from RE­CIST1.1, which Ge­neos CEO Ni­ran­jan Sarde­sai ac­knowl­edged is the gold stan­dard for de­ter­min­ing ob­jec­tive re­spons­es, or changes in tu­mor size.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER